Study Parameters

16-week double-blind clinical trial. n=120 subjects (Fitzpatrick Skin Types III-V). Measurement device utilized: Mexameter® MX 18.

Measured Outcomes

22.4% reduction in targeted epidermal melanin density. 18.5% improvement in overall skin luminance (L* value). 0% incidence of paradoxical hyperpigmentation.

L-Glutathione (50,000ppm): Directly neutralizes free radicals and chemically shifts the melanin synthesis pathway from eumelanin (dark) to pheomelanin (light).

Tranexamic Acid (2.0%): Blocks plasminogen binding to keratinocytes, effectively reducing UV-induced arachidonic acid and prostaglandin production.

Niacinamide (5.0%): Vitamin B3 derivative proven to inhibit melanosome transfer from melanocytes to keratinocytes by up to 68% in vitro.

Cellular Matrix Base: Complex of 18 specific amino acids (focusing on Proline and Glycine) and 9 essential vitamins for immediate structural skin barrier reinforcement.

Dosage Matrix: Administer 0.5 mL to 1.0 mL per specific facial quadrant. Do not exceed 5.0 mL total per session.

Delivery Method: Designed for topical absorption. If utilized with clinical micro-channeling devices, restrict penetration depth to 0.25mm – 0.50mm maximum.

Session Frequency: Execute 1 session every 14 days. Minimum recommended protocol spans 4 consecutive sessions for measurable baseline changes.

Post-Procedure Directives: Mandatory application of broad-spectrum SPF 50+. Strictly avoid AHAs, BHAs, and Retinoids >5% concentration for 72 hours post-application.

PACKAGING SPECIFICATIONS

Volume: 5.0 mL per sterile glass vial.

Unit Configuration: 5 individual vials per commercial box.

Authorized for professional cosmetic application exclusively. Contraindicated for pregnant or nursing individuals. In-vitro and in-vivo clinical percentages provided strictly for professional reference and treatment planning. Always conduct a patch test prior to full administration.